Audience

HCP Other (Non-Derm) panel (US)

HCP Other (Non-Derm) (US): a public Ask Brox audience of Brox clones, each built from a long-form interview with a real person. Every insight fielded on this panel, newest first.

2 insights·0 studies

What did the HCP Other (Non-Derm) panel say?

  1. #

    37.1%

    37.1% (26 of 70) would still prescribe the brand-name medicine they prefer when it costs the patient $150 a month against $5 for an older generic, down from 95.7% (67 of 70) at $25 and 55.7% (39 of 70) at $75; none of the 70 moves back to the brand as the price rises. — Patient out-of-pocket cost and prescribing: US physicians keep a preferred brand at $25 a month, split at $75, and 62.9% switch to a generic at $150

    base 70

  2. #

    22.9%

    22.9% (16 of 70) are likely, a 6 or 7 of 7, to prescribe a new medicine with a clear phase 3 benefit in the next three months when most plans do not cover it and a patient pays about $250 a month, against 72.9% (51 of 70) when it is covered with no prior authorization and a $30 copay, and 54.3% (38 of 70) when prior authorization takes one to two weeks. — New medicine launches: 72.9% of US physicians and other prescribers would try one in its first months when it is covered, 22.9% when patients pay $250 a month

    base 70

What has Brox published on hcp other (non-derm) panel (us)?Newest first

What do people ask about hcp other (non-derm) panel (us)?

How much does a patient's out-of-pocket cost change what a physician is willing to prescribe?
Between $25 and $75 a month: 4.3% of US physicians and other prescribers outside dermatology would pick a $5 generic over the brand-name medicine they prefer when the brand costs the patient $25 a month, 44.3% at $75 and 62.9% at $150 (n=70, November 2026).Read the insight
What makes a physician try a newly launched medicine in its first six months: the trial data, a peer, the rep, or coverage?
Coverage, more than trial data, decides it in practice: 72.9% of US prescribers outside dermatology are likely to prescribe a newly launched medicine with a clear phase 3 benefit in its first months when it is covered without prior authorization, 54.3% when prior authorization is needed and 22.9% when a patient pays $250 a month, even though 55.7% name trial data as their single biggest trigger (n=70, November 2026).Read the insight

Other audiences

How should you read these findings?

Where the numbers come from. Every figure on this site is a predicted response from Brox clones: behavioural replicas of real people, each built from a long-form interview with that person. The base under each figure is the number of clones behind it.

Where the real data comes from. The long-form video interviews with the real people the clones are built from. A quote is always shown with the interview line it was predicted from.

What you can take away. Insights publish their tabulation as CSV and JSON: question, option, count, percentage and base. Never per-person rows.

Ask this of your own customers: humans@brox.ai